Product Description
Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. (Sourced from: https://medlineplus.gov/druginfo/meds/a696011.html)
Mechanisms of Action: NRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ViiV Healthcare
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Cameroon, Canada, Chile, China, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Mexico, Mozambique, Poland, Portugal, Puerto Rico, Russia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 23
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acquired Immunodeficiency Syndrome|Communicable Diseases|Deficiency Diseases|HIV Infections|Pregnancy Outcomes|Tuberculosis
Phase 1: Glioma|Healthy Volunteers|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06428045 |
STARLITE | P1 |
Recruiting |
Glioma |
2029-04-30 |
50% |
2025-06-24 |
Primary Completion Date|Primary Endpoints|Start Date |
ACTRN12621000745842p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Kidney Diseases |
2022-02-28 |
|||
NCT06497465 |
DOVETAIL | P3 |
Recruiting |
Tuberculosis |
2028-01-31 |
33% |
2025-09-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06203132 |
ELDORADO | P3 |
Recruiting |
Communicable Diseases|HIV Infections |
2026-11-01 |
28% |
2025-03-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05979311 |
VOGUE | P3 |
Active, not recruiting |
HIV Infections|Acquired Immunodeficiency Syndrome |
2026-03-24 |
54% |
2025-12-06 |
|
NCT04808973 |
PREGNANCY | P3 |
Completed |
Deficiency Diseases|Acquired Immunodeficiency Syndrome|HIV Infections|Pregnancy Outcomes|Communicable Diseases |
2023-08-31 |
9% |
2023-10-05 |
|
NCT04880785 |
VOLVER | P2 |
Completed |
HIV Infections |
2023-06-12 |
12% |
2025-08-27 |
|
2013-000783-29 |
2013-000783-29 | P2 |
Completed |
HIV Infections |
2023-04-20 |
67% |
2025-06-09 |
Treatments |
2017-001518-27 |
2017-001518-27 | P2 |
Completed |
HIV Infections |
2023-04-13 |
2025-07-09 |
Treatments |
|
2019-001961-34 |
ALTAR | P3 |
Completed |
HIV Infections |
2024-07-02 |
2025-05-06 |
Treatments|Trial Status |
|
2020-003951-13 |
ANRS177DUETTO | P3 |
Completed |
HIV Infections |
2024-05-29 |
2025-05-06 |
Treatments|Trial Status |
|
2018-004885-32 |
DOBINeuro | P3 |
Completed |
HIV Infections |
2023-04-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20191879 |
CTR20191879 | P3 |
Active, not recruiting |
HIV Infections |
None |
2025-04-29 |
Patient Enrollment |
|
NCT07393659 |
PATH | P3 |
Not yet recruiting |
HIV Infections|Acquired Immunodeficiency Syndrome |
2030-12-30 |
67% |
2026-02-10 |
Primary Endpoints|Treatments |
2023-504993-40-00 |
219816 | P3 |
Active, not recruiting |
HIV Infections |
2027-05-28 |
2025-05-02 |
Treatments |
|
2023-503893-19-00 |
219700 | P3 |
Active, not recruiting |
HIV Infections |
2026-08-25 |
41% |
2025-05-02 |
Treatments |
NCT05924438 |
Opti-DOR | P3 |
Active, not recruiting |
HIV Infections |
2026-06-30 |
27% |
2025-04-03 |
Primary Endpoints |
2020-001426-57 |
D3 | P3 |
Active, not recruiting |
HIV Infections |
2026-04-03 |
|||
NCT05917509 |
VOLITION | P3 |
Active, not recruiting |
HIV Infections |
2025-09-16 |
41% |
2025-12-23 |
|
NCT06811246 |
MK-8591-058 | P1 |
Completed |
Healthy Volunteers |
2024-07-14 |
2025-02-07 |
Primary Endpoints|Treatments |
|
2023-508634-34-00 |
ANRS0250s-BI-LIGHT | P2 |
Not yet recruiting |
HIV Infections |
2027-06-30 |
2025-05-02 |
Treatments |
|
NCT06034938 |
DOR | P2 |
Recruiting |
Acquired Immunodeficiency Syndrome |
2026-04-01 |
12% |
2025-08-27 |
Primary Endpoints |
2021-000290-84 |
VOLVER | P2 |
Active, not recruiting |
Unknown |
2023-07-20 |
2022-03-13 |
Treatments |